WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

ATCvet code alterations

Previous ATCvet codeATCvet level name New ATCvet code
QL01XY02pertuzumab and trastuzumabQL01FY01
QL01XY03nivolumab and relatlimabQL01FY02
QL04AA02muromonab-CD3QL04AG01
QL04AA10sirolimusQL04AH01
QL04AA13leflunomideQL04AK01
QL04AA18everolimusQL04AH02
QL04AA21efalizumabQL04AG02
QL04AA23natalizumabQL04AG03
QL04AA25eculizumabQL04AJ01
QL04AA26belimumabQL04AG04
QL04AA27fingolimodQL04AE01
QL04AA29tofacitinibQL04AF01
QL04AA31teriflunomideQL04AK02
QL04AA33vedolizumabQL04AG05
QL04AA34alemtuzumabQL04AG06
QL04AA35begelomabQL04AG07
QL04AA36ocrelizumabQL04AG08
QL04AA37baricitinibQL04AF02
QL04AA38ozanimodQL04AE02
QL04AA39emapalumabQL04AG09
QL04AA42siponimodQL04AE03
QL04AA43ravulizumab QL04AJ02
QL04AA44upadacitinibQL04AF03
QL04AA45filgotinibQL04AF04
QL04AA46itacitinibQL04AF05
QL04AA47inebilizumabQL04AG10
QL04AA49peficitinibQL04AF06
QL04AA50ponesimodQL04AE04
QL04AA51anifrolumabQL04AG11
QL04AA52ofatumumabQL04AG12
QL04AA53teprotumumabQL04AG13
QL04AA54pegcetacoplanQL04AJ03
QL04AA55sutimlimabQL04AJ04
QL04AA56deucravacitinibQL04AF07
QL04AA57ublituximabQL04AG14
QL04AA59avacopanQL04AJ05
QN05CM19suvorexantQN05CJ01
QN05CM21lemborexantQN05CJ02
QP51AX12dinitolmide QP51BX06

Last updated: 2023-12-21